Geode Capital Management LLC Purchases 94,742 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Geode Capital Management LLC lifted its stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 937.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 104,853 shares of the company's stock after acquiring an additional 94,742 shares during the period. Geode Capital Management LLC owned approximately 1.01% of Avalo Therapeutics worth $779,000 at the end of the most recent reporting period.

Wall Street Analyst Weigh In

AVTX has been the topic of a number of recent research reports. Wedbush reiterated an "outperform" rating and issued a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Stifel Nicolaus started coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a "buy" rating and a $36.00 target price for the company. HC Wainwright restated a "neutral" rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Jefferies Financial Group began coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They set a "buy" rating and a $23.00 target price for the company. Finally, Piper Sandler initiated coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an "overweight" rating and a $48.00 target price for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $33.00.

Avalo Therapeutics Trading Down 0.4 %

NASDAQ AVTX traded down $0.02 during trading hours on Monday, hitting $5.02. 29,098 shares of the company's stock were exchanged, compared to its average volume of 52,813. Avalo Therapeutics, Inc. has a 1-year low of $4.15 and a 1-year high of $16.00. The stock has a 50-day simple moving average of $6.37 and a 200 day simple moving average of $8.35.

Avalo Therapeutics Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.